The aim of this study was to evaluate the feasibility of a high-dose intensity and high-dose density multicycle @entity1259 and @entity786 regimen with peripheral blood stem cells (PBSC) and haematopoietic growth factor ( @entity1261 ) support in advanced @entity0 @entity1 . From August 1994 to September 1999, 56 @entity0 @entity1 (8 stage IIIB and 48 stage IV) received 205 courses of @entity786 3 g x m(-2) and @entity1259 100 mg x m(-2) every 14 days. @entity1261 5 microg x kg(-1) x day(-1) was administered from day 3 to neutrophil recovery. 4 courses were planned. PBSC were collected after course 1, and reinfused after courses 3 and 4, with > or = 2 x 10(6) CD34+ PBSC x kg(-1) required for each reinfusion. 48 @entity1 (86%) received all 4 planned courses. Early withdrawal was consecutive to infectious complications (n = 4), severe @entity1395 (n = 3), @entity548 (n = 1). A median number of 10.8 x 10(6) CD34+ PBSC x kg(-1) (range, 3-80) was harvested with 1 or 2 apheresis in 48 @entity1 (94%). Median relative dose intensity was 91.3% (range, 72-102%). Grade 4 neutrophil @entity137 was observed in 100% of @entity1 . @entity1398 was observed in 40% of courses (median duration 2 days). Red blood cells and platelets had to be transfused in 54% and 27% of courses, respectively. There were no toxic deaths. Objective response rate was 69% in stage IV @entity1 (31/45 evaluable pts), with a 16% complete response rate. Their median progression-free and overall survivals were 22.5 and 37 months, respectively. This epirubicine-containing high-dose regimen appeared feasible, albeit with high @entity137 . Time-related progression parameters exceed commonly reported ones. Controlled studies of upfront sequential high-dose chemotherapy are still needed to evaluate its real benefit.

High-dose sequential @entity1259 and XXXX with peripheral blood stem cell support for advanced @entity0 : results of a phase II study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity1261 :: ('1440', 'Gene') :: ['G-CSF'] @entity548 :: ('MESH:D006470', 'Disease') :: ['haemorrhagic cystitis'] @entity1259 :: ('MESH:D015251', 'Chemical') :: ['epirubicin'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity1395 :: ('MESH:D001247', 'Disease') :: ['asthenia'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['Febrile neutropenia']
@entity786 :: (MESH:D003520,Chemical) :: ['cyclophosphamide']
